Compare CSTL & SXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTL | SXC |
|---|---|---|
| Founded | 2007 | 1960 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Steel/Iron Ore |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 661.7M | 549.5M |
| IPO Year | 2019 | N/A |
| Metric | CSTL | SXC |
|---|---|---|
| Price | $39.54 | $6.47 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $38.67 | $10.00 |
| AVG Volume (30 Days) | 588.2K | ★ 1.6M |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 7.36% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.75 |
| Revenue | $343,530,000.00 | ★ $1,843,100,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.70 |
| Revenue Growth | ★ 10.15 | N/A |
| 52 Week Low | $14.59 | $6.24 |
| 52 Week High | $40.61 | $12.71 |
| Indicator | CSTL | SXC |
|---|---|---|
| Relative Strength Index (RSI) | 80.57 | 36.65 |
| Support Level | $33.03 | $6.24 |
| Resistance Level | $35.49 | $6.60 |
| Average True Range (ATR) | 1.56 | 0.21 |
| MACD | 0.33 | 0.02 |
| Stochastic Oscillator | 85.93 | 30.43 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is primarily used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through three segments: Domestic Coke, Brazil Coke, and Logistics. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.